Literature DB >> 21888615

Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.

Disni Muringampurath-John, Christopher R Flowers, Michael Toscano, Chen Zhengjia, Jonathan L Kaufman, Martha Arellano, Leon Bernal-Mizrachi, Leonard T Heffner, Mary-Jo Lechowicz, Morgan McLemore, Elliott Winton, David L Jaye, Sagar Lonial, Hanna Jean Khoury.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21888615     DOI： 10.3109/10428194.2011.619019

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  PET-derived tumor metrics predict DLBCL response and progression-free survival.

Authors:  Prioty Islam; Jordan Goldstein; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-02-04

2.  Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma.

Authors:  Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Jean L Koff; Ashley D Staton; Jagpreet Chhatwal; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2015-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.